EU Business Round-Up: BioGaia Creates Investment Arm, Boiron Grows In Spain, GSK Ends Hikma Talks
Executive Summary
Latest European consumer health business news: BioGaia sets up an investment arm to identify interesting start-ups, France's Boiron expands its Spain offering with Iprad deal, and GSK ends talks with Hikma over the sale of its Egyptian OTC business.
You may also be interested in...
France's Boiron Strikes Deal With Bionorica As Q3 Sales Edge Up
Boiron has gained the rights to distribute Bionorica's Canephron herbal medicine in France as it continues to diversify its portfolio away from homeopathy.
Hikma Opens Discussions To Acquire GSK OTC, Rx Businesses In Egypt, Tunisia
With operations in the MENA region already tracking to $700m in revenues for 2020, Hikma is looking to grow the business further after beginning negotiations with GSK to buy certain of the originator’s businesses in Egypt and Tunisia.
France's Boiron Diversifies Into Probiotics To Arrest Sales Decline
Homeopathy specialist Boiron its diversifying its offering into the increasingly popular probiotics segment with launches underway in France, Italy and Spain, as well as Eastern Europe.